Could psychedelics fight inflammation? What the October 2026 Parkinson's data show

As of 21 October 2026, the answer is: possibly, and it is very early. NPR reported that day on what it described as some of the first evidence in humans that psychedelics may hold potential for treating diseases characterised by inflammation and immune dysregulation throughout the body. The data come from a small study of people with Parkinson's disease, published in JAMA Psychiatry, and the researchers themselves stress its limits.

Why would a mind-altering drug touch inflammation? NPR explained that psilocybin and LSD bind tightly to serotonin receptors that densely populate certain structures of the brain. Many cells and tissues beyond the brain have the same receptors, known as 5-HT2A, so researchers have started to probe what else these drugs do.

In the new analysis, a team at the University of California, San Francisco used blood tests to measure five signalling molecules involved in inflammation, before and after two sessions with psilocybin. Participants had significantly lower levels of inflammation after the treatments compared with baseline, and the changes persisted a month after their final dose. A blood marker of stress in the mitochondria, the cells' energy factories, improved immediately afterwards but not at the longer follow-up.

Now the caveats, which the researchers emphasise. The findings were based on 12 participants in a pilot study to test feasibility and safety. There was no control group, and participants knew they were receiving the drug. One of the co-authors said the data need confirming in follow-up studies before definitive claims. A signal to investigate is not yet proof.